Literature DB >> 22221966

Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study).

Kiyoshi Migita1, Yukio Watanabe, Yuka Jiuchi, Yoko Nakamura, Akira Saito, Michiyasu Yagura, Hajime Ohta, Masaaki Shimada, Eiji Mita, Taizo Hijioka, Haruhiro Yamashita, Eiichi Takezaki, Toyokichi Muro, Hironori Sakai, Makoto Nakamuta, Seigo Abiru, Atsumasa Komori, Masahiro Ito, Hiroshi Yatsuhashi, Minoru Nakamura, Hiromi Ishibashi.   

Abstract

BACKGROUND/AIMS: Although the outcome of autoimmune hepatitis (AIH) is generally good, the natural course and likelihood of progression to cirrhosis or hepatocellular carcinoma (HCC) remain undefined, and may vary by region and population structure. Our aims were to evaluate risk factors that contribute to poor outcome and particularly development of HCC in a prospective multicentric cohort study of AIH.
METHODS: The study group comprised 193 Japanese patients with AIH who were prospectively followed up at annual intervals between 1995 and 2008. The mean follow-up period was 8.0 ± 4.5 years.
RESULTS: Twenty-one (10.9%) patients had cirrhosis at presentation and a further 15 (7.8%) developed cirrhosis during the follow-up period. Survival rates were 94.2% at 10 years and 89.3% at 15 years. HCC was diagnosed in seven of the 193 patients. The presence of cirrhosis at presentation was a risk factor for HCC according to a Cox proportional hazard model, and the HCC-free survival rate was significantly lower in those with cirrhosis compared to those without cirrhosis according to Kaplan-Meier analysis.
CONCLUSIONS: Although the outcome of AIH is as good if not better among Japanese than for other populations, there was an increased risk of HCC in these patients. Cirrhosis at presentation was predictive of development of HCC in AIH in Japan.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 22221966     DOI: 10.1111/j.1478-3231.2011.02734.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  26 in total

1.  Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.

Authors:  Hiroshi Matsumura; Kazushige Nirei; Hitomi Nakamura; Teruhisa Higuchi; Yasuo Arakawa; Masahiro Ogawa; Naohide Tanaka; Mitsuhiko Moriyama
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

Review 2.  Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis.

Authors:  Aylin Tansel; Lior H Katz; Hashem B El-Serag; Aaron P Thrift; Mayur Parepally; Mohammad H Shakhatreh; Fasiha Kanwal
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-12       Impact factor: 11.382

Review 3.  Current concepts in the diagnosis and management of autoimmune hepatitis.

Authors:  Stephen Kriese; Michael A Heneghan
Journal:  Frontline Gastroenterol       Date:  2012-11-12

4.  Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis.

Authors:  Lara Dakhoul; Keaton R Jones; Samer Gawrieh; Marwan Ghabril; Chelsey McShane; Raj Vuppalanchi; Eduardo Vilar-Gomez; Lauren Nephew; Naga Chalasani; Craig Lammert
Journal:  Dig Dis Sci       Date:  2019-01-07       Impact factor: 3.199

5.  MicroRNA301 is a potential diagnostic biomarker for hepatocellular cancer.

Authors:  Kun He; Zemin Hu; Jiahou Ruan; Qianhong Ma; Feng Zhong; Xinsheng Cheng; Shibo Sun; Jie Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; George K Koukoulis; George N Dalekos
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

7.  Association of a single nucleotide polymorphism in TNIP1 with type-1 autoimmune hepatitis in the Japanese population.

Authors:  Shomi Oka; Takashi Higuchi; Hiroshi Furukawa; Minoru Nakamura; Atsumasa Komori; Seigo Abiru; Shinya Nagaoka; Satoru Hashimoto; Atsushi Naganuma; Noriaki Naeshiro; Kaname Yoshizawa; Masaaki Shimada; Hideo Nishimura; Minoru Tomizawa; Masahiro Kikuchi; Fujio Makita; Haruhiro Yamashita; Keisuke Ario; Hiroshi Yatsuhashi; Shigeto Tohma; Aya Kawasaki; Naoyuki Tsuchiya; Kiyoshi Migita
Journal:  J Hum Genet       Date:  2018-03-20       Impact factor: 3.172

Review 8.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

Review 9.  Auto immune hepatitis.

Authors:  Nicole Mf van Gerven; Ynto S de Boer; Chris Jj Mulder; Carin Mj van Nieuwkerk; Gerd Bouma
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

10.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.